Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'"

J Hepatol. 2018 Apr;68(4):864-866. doi: 10.1016/j.jhep.2017.11.044. Epub 2018 Jan 12.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antiviral Agents*
  • Developing Countries
  • England
  • Hepatitis C*
  • Hepatitis C, Chronic*
  • Humans
  • State Medicine


  • Antiviral Agents